Abstract
Rationale: Isoleucine (ILE) is known to modulate glucose metabolism, but it remains unclear if daily ILE supplementation is able to lower fasting and 24-hour plasma glucose concentrations in patients with type 2 diabetes (T2D).
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
